CRAD001L2201
Laufzeit: 01.01.2009 - 31.12.2010
Kurzfassung
A randomized, open label, multicenter phase II study to compare RAD001 plus Bevacizumab versus Interferon alpha-2a and Bevacizumab for the first-line treatment of patients with met. clear cell carcinoma of the kidney
